Characterization of RO4583298 as a novel potent, dual antagonist with in vivo activity at tachykinin NK 1 and NK 3 receptors

British Journal of Pharmacology

Volumn 162, Issue 4, 2011, Pages 929-946

  Malherbe, P ^a   Knoflach, F ^a   Hernandez, M C ^a   Hoffmann, T ^a   Schnider, P ^a   Porter, R H ^a   Wettstein, J G ^a   Ballard, T M ^a   Spooren, W ^a   Steward, L ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

dopaminergic neurone; dual NK 1 NK 3 antagonist; firing frequency; gerbil foot tapping, mouse tail whips; GR73632; inositol phosphate accumulation; neurokinin; RO4583298; Schild analysis; senktide

Indexed keywords

2 BENZHYDRYL 3 (2 METHOXYBENZYLAMINO) 1 AZABICYCLO[2.2.2]OCTANE; 2 PHENYL N (PYRIDIN 3 YL) N METHYLISOBUTYRAMIDE; APREPITANT; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR ANTAGONIST; NEUROKININ 3 RECEPTOR; NEUROKININ 3 RECEPTOR ANTAGONIST; RO 4583298; SENKTIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BRAIN ELECTROPHYSIOLOGY; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SCREENING; FEMALE; GERBIL; GUINEA PIG; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RECEPTOR BLOCKING; SUBSTANTIA NIGRA;

ACTION POTENTIALS; AMIDES; ANIMALS; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GERBILLINAE; GUINEA PIGS; HEK293 CELLS; HUMANS; INOSITOL; LIGANDS; MACACA FASCICULARIS; MALE; MESENCEPHALON; MICE; NEURONS; PHOSPHORYLATION; PYRIDINES; RATS; RECEPTORS, NEUROKININ-1; RECEPTORS, NEUROKININ-3; SCHIZOPHRENIA; SUBSTANCE P; SUBSTANTIA NIGRA;

EID: 79251524926     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.01096.x     Document Type: Article

References (60)

1. Acsady L, Katona I, Gulyas AI, Shigemoto R, Freund TF, (1997). Immunostaining for substance P receptor labels GABAergic cells with distinct termination patterns in the hippocampus. J Comp Neurol 378: 320-336.
2. Alexander SP, Mathie A, Peters JA, (2008). Guide to Receptors and Channels (GRAC), 3rd edition. Br J Pharmacol 153: S1-S209.
3. Almeida TA, Rojo J, Nieto PM, Pinto FM, Hernandez M, Martin JD, et al. (2004). Tachykinins and tachykinin receptors: structure and activity relationships. Curr Med Chem 11: 2045-2081.
4. Ballard TM, Sanger S, Higgins GA, (2001). Inhibition of shock-induced foot tapping behaviour in the gerbil by a tachykinin NK1 receptor antagonist. Eur J Pharmacol 412: 255-264.
5. Blier P, Gobbi G, Haddjeri N, Santarelli L, Mathew G, Hen R, (2004). Impact of substance P receptor antagonism on the serotonin and norepinephrine systems: relevance to the antidepressant/anxiolytic response. J Psychiatry Neurosci 29: 208-218.
6. Cao YQ, Mantyh PW, Carlson EJ. Gillespie AM, Epstein CJ, Basbaum AL, (1998). Primary afferent tachykinins are required to experience moderate to intense pain. Nature 392: 390-394.
7. Chung FZ, Wu LH, Tian Y, Vartanian MA, Lee H, Bikker J, et al. (1995). Two classes of structurally different antagonists display similar species preference for the human tachykinin neurokinin3 receptor. Mol Pharmacol 48: 711-716.
8. Dawson LA, Cato KJ, Scott C, Watson JM, Wood MD, Foxton R, et al. (2008). In vitro and in vivo characterization of the non-peptide NK3 receptor antagonist SB-223412 (talnetant): potential therapeutic utility in the treatment of schizophrenia. Neuropsychopharmacology 33: 1642-1652.
9. Ebner K, Muigg P, Singewald G, Singewald N, (2008). Substance P in stress and anxiety: NK-1 receptor antagonism interacts with key brain areas of the stress circuitry. Ann N Y Acad Sci 1144: 61-73.
10. Ebner K, Sartori SB, Singewald N, (2009). Tachykinin receptors as therapeutic targets in stress-related disorders. Curr Pharm Des 15: 1647-1674.
11. Emonds-Alt X, Bichon D, Ducoux JP, Heaulme M, Miloux B, Poncelet M, et al. (1995). SR 142801, the first potent non-peptide antagonist of the tachykinin NK3 receptor. Life Sci 56: PL27-PL32.
12. Evangelista S, (2005). Talnetant GlaxoSmithKline. Curr Opin Investig Drugs 6: 717-721.
13. Grace AA, Onn SP, (1989). Morphology and electrophysiological properties of immunocytochemically identified rat dopamine neurons recorded in vitro. J Neurosci 9: 3463-3481.
14. Grady EF, Garland AM, Gamp PD, Lovett M, Payan DG, Bunnett NW, (1995). Delineation of the endocytic pathway of substance P and its seven-transmembrane domain NK1 receptor. Mol Biol Cell 6: 509-524.
15. Hale JJ, Mills SG, MacCoss M, Finke PE, Cascieri MA, Sadowski S, et al. (1998). Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl) phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl) methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist. J Med Chem 41: 4607-4614.
16. Harrison PJ, (1999). The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain 122: 593-624.
17. Hill R, (2000). NK1 (substance P) receptor antagonists-why are they not analgesic in humans? Trends Pharmacol Sci 21: 244-246.
18. Hoffmann T, Koblet A, Peters J-U, Schnider P, Sleight A, Stadler H, (2005). Preparation of 2-phenyl-N-(pyridin-3-yl)-N-methylisobutyramide derivatives as dual NK1/NK3 antagonists for treating schizophrenia. WO 2005/002577 A1.
19. Jenkinson KM, Mann PT, Southwell BR, Furness JB, (2000). Independent endocytosis of the NK(1) and NK(3) tachykinin receptors in neurons of the rat myenteric plexus. Neuroscience 100: 191-199.
20. Koutcherov Y, Ashwell KW, Paxinos G, (2000). The distribution of the neurokinin B receptor in the human and rat hypothalamus. Neuroreport 11: 3127-3131.
21. Langlois X, Wintmolders C, te Riele P, Leysen JE, Jurzak M, (2001). Detailed distribution of Neurokinin 3 receptors in the rat, guinea pig and gerbil brain: a comparative autoradiographic study. Neuropharmacology 40: 242-253.
22. Lecci A, Maggi CA, (2003). Peripheral tachykinin receptors as potential therapeutic targets in visceral diseases. Expert Opin Ther Targets 7: 343-362.
23. Leffler A, Ahlstedt I, Engberg S, Svensson A, Billger M, Oberg L, et al. (2009). Characterization of species-related differences in the pharmacology of tachykinin NK receptors 1, 2 and 3. Biochem Pharmacol 77: 1522-1530.
24. Leucht S, Wahlbeck K, Hamann J, Kissling W, (2003). New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 361: 1581-1589.
25. Liem-Moolenaar M, Gray FA, de Visser SJ, Franson KL, Schoemaker RC, Schmitt JA, et al. (2010). Psychomotor and cognitive effects of a single oral dose of talnetant (SB223412) in healthy volunteers compared with placebo or haloperidol. J Psychopharmacol 24: 73-82.
26. Lindstrom E, von Mentzer B, Pahlman I, Ahlstedt I, Uvebrant A, Kristensson E, et al. (2007). Neurokinin 1 receptor antagonists: correlation between in vitro receptor interaction and in vivo efficacy. J Pharmacol Exp Ther 322: 1286-1293.
27. Lowe JA 3rd, Drozda SE, Snider RM, Longo KP, Zorn SH, Morrone J, et al. (1992). The discovery of (2S,3S)-cis-2-(diphenylmethyl)-N-[(2-methoxyphenyl) methyl]-1- azabicyclo[2.2.2]-octan-3-amine as a novel, nonpeptide substance P antagonisst. J Med Chem 35: 2591-2600.
28. Malherbe P, Bissantz C, Marcuz A, Kratzeisen C, Zenner MT, Wettstein JG, et al. (2008). Me-talnetant and osanetant interact within overlapping but not identical binding pockets in the human tachykinin neurokinin 3 receptor transmembrane domains. Mol Pharmacol 73: 1736-1750.
29. Malherbe P, Kratzeisen C, Marcuz A, Zenner MT, Nettekoven MH, Ratni H, et al. (2009). Identification of a Critical Residue in the Transmembrane Domain 2 of Tachykinin Neurokinin 3 Receptor Affecting the Dissociation Kinetics and Antagonism Mode of Osanetant (SR 142801) and Piperidine-Based Structures. J Med Chem 52: 7103-7112.
30. Marco N, Thirion A, Mons G, Bougault I, Le Fur G, Soubrie P, et al. (1998). Activation of dopaminergic and cholinergic neurotransmission by tachykinin NK3 receptor stimulation: an in vivo microdialysis approach in guinea pig. Neuropeptides 32: 481-488.
31. Maubach KA, Martin K, Smith DW, Hewson L, Frankshun RA, Harrison T, et al. (2001). Substance P stimulates inhibitory synaptic transmission in the guinea pig basolateral amygdala in vitro. Neuropharmacology 40: 806-817.
32. Meltzer H, Prus A, (2006). NK3 receptor antagonists for the treatment of schizophrenia. Drug Discov Today Ther Strat 3: 555-560.
33. Meltzer HY, Arvanitis L, Bauer D, Rein W, (2004). Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am J Psychiatry 161: 975-984.
34. Mileusnic D, Lee JM, Magnuson DJ, Hejna MJ, Krause JE, Lorens JB, et al. (1999a). Neurokinin-3 receptor distribution in rat and human brain: an immunohistochemical study. Neuroscience 89: 1269-1290.
35. Mileusnic D, Magnuson DJ, Hejna MJ, Lorens JB, Lorens SA, Lee JM, (1999b). Age and species-dependent differences in the neurokinin B system in rat and human brain. Neurobiol Aging 20: 19-35.
36. Nagano M, Saitow F, Haneda E, Konishi S, Hayashi M, Suzuki H, (2006). Distribution and pharmacological characterization of primate NK-1 and NK-3 tachykinin receptors in the central nervous system of the rhesus monkey. Br J Pharmacol 147: 316-323.
37. Nalivaiko E, Michaud JC, Soubrie P, Le Fur G, Feltz P, (1997). Tachykinin neurokinin-1 and neurokinin-3 receptor-mediated responses in guinea-pig substantia nigra: an in vitro electrophysiological study. Neuroscience 78: 745-757.
38. Nordquist RE, Delenclos M, Ballard TM, Savignac H, Pauly-Evers M, Ozmen L, et al. (2008a). Cognitive performance in neurokinin 3 receptor knockout mice. Psychopharmacology (Berl) 198: 211-220.
39. Nordquist RE, Durkin S, Jacquet A, Spooren W, (2008b). The tachykinin NK3 receptor agonist senktide induces locomotor activity in male Mongolian gerbils. Eur J Pharmacol 600: 87-92.
40. Nordquist RE, Ballard TM, Algeyer B, Pauly-Evers M, Ozmen L, Spooren W, (2010). Pharmacological characterization of senktide-induced tail whips. Neuropharmacology 58: 259-267.
41. Ogier R, Raggenbass M, (2003). Action of tachykinins in the rat hippocampus: modulation of inhibitory synaptic transmission. Eur J Neurosci 17: 2639-2647.
42. Otsuka M, Yoshioka K, (1993). Neurotransmitter functions of mammalian tachykinins. Physiol Rev 73: 229-308.
43. Peters JU, Hoffmann T, Schnider P, Stadler H, Koblet A, Alker A, et al. (2010). Discovery of potent, balanced and orally active dual NK1/NK3 receptor ligands. Bioorg Med Chem Lett 20: 3405-3408.
44. Quartara L, Altamura M, Evangelista S, Maggi CA, (2009). Tachykinin receptor antagonists in clinical trials. Expert Opin Investig Drugs 18: 1843-1864.
45. Ribeiro-da-Silva A, Hokfelt T, (2000). Neuroanatomical localisation of Substance P in the CNS and sensory neurons. Neuropeptides 34: 256-271.
46. Rigby M, O'Donnell R, Rupniak NM, (2005). Species differences in tachykinin receptor distribution: further evidence that the substance P (NK1) receptor predominates in human brain. J Comp Neurol 490: 335-353.
47. Rupniak NMJ, Williams AR, (1994). Differential inhibition of foot tapping and chromodacryorrhoea in gerbils by CNS penetrant and non-penetrant tachykinin NK1 receptor antagonists. Eur J Pharmacol 265: 179-183.
48. Santarelli L, Gobbi G, Debs PC, Sibille ET, Blier P, Hen R, et al. (2001). Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotonergic function. Proc Natl Acad Sci USA 98: 1912-1917.
49. Sarau HM, Griswold DE, Potts W, Foley JJ, Schmidt DB, Webb EF, et al. (1997). Nonpeptide tachykinin receptor antagonists: I. Pharmacological and pharmacokinetic characterization of SB 223412, a novel, potent and selective neurokinin-3 receptor antagonist. J Pharmacol Exp Ther 281: 1303-1311.
50. Sarau HM, Griswold DE, Bush B, Potts W, Sandhu P, Lundberg D, et al. (2000). Nonpeptide tachykinin receptor antagonists. II. Pharmacological and pharmacokinetic profile of SB-222200, a central nervous system penetrant, potent and selective NK-3 receptor antagonist. J Pharmacol Exp Ther 295: 373-381.
51. Sarau HM, Feild JA, Ames RS, Foley JJ, Nuthulaganti P, Schmidt DB, et al. (2001). Molecular and pharmacological characterization of the murine tachykinin NK(3) receptor. Eur J Pharmacol 413: 143-150.
52. Schmidlin F, Dery O, Bunnett NW, Grady EF, (2002). Heterologous regulation of trafficking and signaling of G protein-coupled receptors: beta-arrestin-dependent interactions between neurokinin receptors. Proc Natl Acad Sci USA 99: 3324-3329.
53. Schmidlin F, Roosterman D, Bunnett NW, (2003). The third intracellular loop and carboxyl tail of neurokinin 1 and 3 receptors determine interactions with beta-arrestins. Am J Physiol Cell Physiol 285: C945-C958.
54. Shughrue PJ, Lane MV, Merchenthaler I, (1996). In situ hybridization analysis of the distribution of neurokinin-3 mRNA in the rat central nervous system. J Comp Neurol 372: 395-414.
55. Spooren W, Riemer C, Meltzer H, (2005). Opinion: NK3 receptor antagonists: the next generation of antipsychotics? Nat Rev Drug Discov 4: 967-975.
56. Stoessl AJ, (1994). Localization of striatal and nigral tachykinin receptors in the rat. Brain Res 646: 13-18.
57. Tamminga CA, Holcomb HH, (2005). Phenotype of schizophrenia: a review and formulation. Mol Psychiatry 10: 27-39.
58. Tooney PA, Au GG, Chahl LA, (2000). Localisation of tachykinin NK1 and NK3 receptors in the human prefrontal and visual cortex. Neurosci Lett 283: 185-188.
59. Urban LA, Fox AJ, (2000). NK1 receptor antagonists-are they really without effect in the pain clinic? Trends Pharmacol Sci 21: 462-464.
60. Wu LH, Vartanian MA, Oxender DL, Chung FZ, (1994). Identification of methionine134 and alanine146 in the second transmembrane segment of the human tachykinin NK3 receptor as reduces involved in species-selective binding to SR 48968. Biochem Biophys Res Commun 198: 961-966.